Published in Pulm Circ on March 01, 2016
Severe pulmonary hypertension in aging female apolipoprotein E-deficient mice is rescued by estrogen replacement therapy. Biol Sex Differ (2017) 0.75
Gender, Estrogen, and Obliterative Lesions in the Lung. Int J Endocrinol (2017) 0.75
High-throughput analysis reveals novel maternal germline RNAs crucial for primordial germ cell preservation and proper migration. Development (2017) 0.75
Update on novel targets and potential treatment avenues in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2016) 0.75
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med (1991) 13.21
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med (1996) 11.76
Ventricular weight in cardiac hypertrophy. Br Heart J (1952) 8.08
The protective effects of estrogen on the cardiovascular system. N Engl J Med (1999) 6.25
Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med (2006) 6.06
Estrogen receptors and human disease. J Clin Invest (2006) 4.91
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest (2009) 4.08
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85
Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, prostacyclin and endothelin-1 pathways. Eur Respir J (2012) 2.72
Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol (2011) 2.39
Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett (2004) 2.17
Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res (2000) 2.08
Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation (2012) 2.04
Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol (2010) 2.03
Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med (2012) 2.00
17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med (2012) 1.95
The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. Chest (2014) 1.93
Estrogen rescues preexisting severe pulmonary hypertension in rats. Am J Respir Crit Care Med (2011) 1.91
Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res (2006) 1.85
Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology (2003) 1.77
Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J (2009) 1.68
FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest (2013) 1.65
Sex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells. Am J Respir Crit Care Med (2015) 1.60
Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol (1988) 1.57
Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology (2006) 1.57
The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol (2011) 1.54
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res (2005) 1.48
Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation (1999) 1.42
Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation (2004) 1.41
Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation (2005) 1.40
Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res (2005) 1.34
Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res (2001) 1.28
Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest (2008) 1.27
Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis (2004) 1.25
Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Am J Physiol Endocrinol Metab (2007) 1.19
Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism (2001) 1.17
The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res (2010) 1.15
The genetic basis of pulmonary arterial hypertension. Hum Genet (2014) 1.14
Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension (2006) 1.12
Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Respir Res (2011) 1.11
Reactive oxygen species and antioxidants in pulmonary hypertension. Antioxid Redox Signal (2012) 1.04
Gender, sex hormones and pulmonary hypertension. Pulm Circ (2013) 1.02
An o-quinone form of estrogen produces free radicals in human breast cancer cells: correlation with DNA damage. Chem Res Toxicol (1994) 1.02
Sex-dependent influence of endogenous estrogen in pulmonary hypertension. Am J Respir Crit Care Med (2014) 1.02
Contribution of oxidative stress to pulmonary arterial hypertension. World J Cardiol (2010) 1.00
Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats. Respir Res (2010) 1.00
Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiol Genomics (2011) 0.97
Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. Br J Pharmacol (2014) 0.97
Exogenous estrogen rapidly attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction. Shock (2008) 0.97
Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension. Pulm Circ (2013) 0.95
BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ (2012) 0.95
Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension. Cardiovasc Res (2013) 0.90
Modulation of human cytochrome P450 1B1 expression by 2,4,3',5'-tetramethoxystilbene. Drug Metab Dispos (2005) 0.89
Characterization of DNA damage induced by 3,4-estrone-o-quinone in human cells. J Biol Chem (1991) 0.89
Estrogen metabolism within the lung and its modulation by tobacco smoke. Carcinogenesis (2012) 0.88
Oestrogen receptor alpha in pulmonary hypertension. Cardiovasc Res (2015) 0.85
Aminorex, dexfenfluramine, and primary pulmonary hypertension. J Clin Epidemiol (1998) 0.80
Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine. Expert Rev Vaccines (2008) 0.80